CM
ADVM

CM Management’s Adverum Biotechnologies ADVM Stock Holding History

CM Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-37,500
Closed -$269K – 74
2023
Q1 		$269K Buy
37,500
+27,500
+275% +$194K 0.32% 55
2022
Q4 		$58K Buy
+10,000
New +$75.8K 0.07% 71

Other funds holding ADVM

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

CM Management's ADVM Position: Q2 2023 in Review

CM Management sold out of Adverum Biotechnologies (ADVM) in Q2 2023, closing a stake of 37,500 shares — an estimated $269K sold.

CM Management first reported a position in ADVM in Q4 2022 and held it in 2 quarters. The position peaked at $269K in Q1 2023. 57 funds tracked by Wall St. Rank hold ADVM as of Q2 2023.

  • CM Management reported no remaining Adverum Biotechnologies position as of Q2 2023 after selling out during the quarter.
  • CM Management sold 37,500 Adverum Biotechnologies shares in Q2 2023, an estimated $269K.
  • CM Management first reported a position in Adverum Biotechnologies in Q4 2022 and held it in 2 quarters.
  • CM Management's Adverum Biotechnologies position peaked at $269K in Q1 2023.
  • 57 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2023.

Based on CM Management's 13F filing for Q2 2023, filed 4 Aug 2023.